Inventiva (NASDAQ:IVA) Stock Jumps 7.8% - Here's What Happened

Key Points

• Inventiva shares rose 7.8% to $3.095 on Thursday, reaching an intraday high of $3.13, while trading volume fell 23% below its average.
• Analysts maintain a broadly positive outlook, with a consensus “Buy” rating and an average price target of $15.86; Guggenheim and Truist recently raised their targets to $14 and $18, respectively.
• Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, its lead oral drug candidate being tested in the Phase 3 NATiV3 trial for metabolic dysfunction-associated steatohepatitis (MASH).

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s stock price was up 7.8% during trading on Thursday. The company traded as high as $3.13 and last traded at $3.0950. Approximately 717,502 shares traded hands during trading, a decline of 23% from the average daily volume of 926,099 shares. The stock had previously closed at $2.87.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Inventiva from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, October 8th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research report on Friday, July 17th. They issued an "overweight" rating for the company. Wall Street Zen upgraded shares of Inventiva from a "sell" rating to a "hold" rating in a research note on Saturday, October 3rd. Guggenheim raised their price target on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, September 15th. Finally, Truist Financial lifted their price objective on Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a report on Friday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $15.86.

Inventiva Price Performance

The company has a 50 day moving average of $4.11 and a 200 day moving average of $4.50.

Inventiva (NASDAQ:IVA - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $0.75 million during the quarter. Equities analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

Several large investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva during the 1st quarter worth about $1,111,000. Persistent Asset Partners Ltd bought a new position in Inventiva during the 4th quarter valued at about $603,000. Engineers Gate Manager LP boosted its position in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after buying an additional 43,280 shares in the last quarter. Finally, Platt Investment Counsel LLC acquired a new position in Inventiva in the third quarter valued at about $45,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.